Last reviewed · How we verify

Asofarma de México S.A de C.V. — Portfolio Competitive Intelligence Brief

Asofarma de México S.A de C.V. pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
PLA (Panto+Levoflox+Azithro) PLA (Panto+Levoflox+Azithro) phase 3 Combination therapy (proton pump inhibitor + fluoroquinolone + macrolide) Gastroenterology / Infectious Disease
CLA (Clarithro+Lanso+Amoxi) CLA (Clarithro+Lanso+Amoxi) phase 3 Antibiotic combination with proton pump inhibitor H. pylori bacterial ribosomes (clarithromycin); H. pylori cell wall (amoxicillin); gastric H+/K+-ATPase (lansoprazole) Gastroenterology / Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Asofarma de México S.A de C.V.:

Cite this brief

Drug Landscape (2026). Asofarma de México S.A de C.V. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/asofarma-de-m-xico-s-a-de-c-v. Accessed 2026-05-17.

Related